CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (19,865)	$ (17,609)
Net loss attributable to non-controlling interest	(4,736)	(3,496)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	512	523
Amortization of intangible assets	2,628	2,736
Amortization of deferred consulting fees	0	19
Amortization of deferred license fees	55	55
Amortization of prepaid rent in common stock	42	42
Stock-based compensation	3,700	2,212
Amortization of discount on related party convertible debt	119	0
Accrued interest on related party convertible debt	9	0
Loss on sale or write-off of equipment	0	21
Write-off for uncollectible receivables	0	(16)
Deferred income tax benefit	(2,448)	(2,862)
Changes in operating assets and liabilities:
Accounts receivable, net	4	(37)
Grant receivable	65	(133)
Inventory	(30)	(79)
Prepaid expenses and other current assets	(301)	(315)
Accounts payable and accrued liabilities	(811)	(2,035)
Other long-term liabilities	1	(186)
Deferred grant income	1,930	0
Deferred rent liabilities	(61)	(10)
Deferred revenues	151	35
Net cash used in operating activities	(19,036)	(21,135)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(305)	(405)
Payments on construction in progress (see Note 4)	(2,518)	0
Proceeds from the sale of equipment	0	4
Security deposit paid, net	(3)	(306)
Cash used in investing activities	(2,826)	(707)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	621	220
Proceeds from sale of preferred stock	0	3,500
Proceeds from issuance of common shares	0	14,724
Fees paid on sale of common shares	0	(302)
Proceeds from exercise of warrants	19	0
Proceeds from sale of treasury stock and subsidiary warrants	11,700	13,582
Reimbursement from landlord on construction in progress (see Note 4)	560	0
Proceeds from issuance of related party convertible debt (see Note 8)	188	0
Repayment of capital lease obligation	(28)	0
Proceeds from sale of common shares of subsidiaries	11,586	468
Fees paid on sale of common shares of subsidiary	(597)	0
Proceeds from exercise of subsidiary stock options	23	0
Net cash provided by financing activities	24,072	32,192
Effect of exchange rate changes on cash and cash equivalents	(232)	(123)
NET CHANGE IN CASH AND CASH EQUIVALENTS:	1,978	10,227
CASH AND CASH EQUIVALENTS:
At beginning of the period	29,487	5,495
At end of the period	$ 31,465	$ 15,722